Evidence map›Paper›PMID 42110550›Full record

ArticleFrontiers in pharmacology2026

Benzofuran compound from

Peiying Wu, Xiaomei Gong, Wenyu Zhang, Dandan Mo, Lili He, Zhijun Song, Chunli Ou, Meng Li, Xiaolei Zhou, Xingyu Xiao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peiying Wu *National Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Xiaomei Gong *National Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Wenyu ZhangDepartment of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, China.
Dandan MoGuangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Lili HeNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Zhijun SongNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Chunli OuGuangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Meng LiNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Xiaolei ZhouGuangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Xingyu XiaoNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Xianghua XiaNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.
Shuo WangNational Engineering Research Center of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Shandougen (SDG), the dried root and rhizome of Objective: This study aimed to identify the bioactive monomers underlying SDG's anti-NPC efficacy and elucidate their molecular mechanisms. Methods: Guided by HPLC fingerprinting, targeted isolation and purification of components from the active fraction were performed. 13 compounds were screened for activity, with benzofuran compound 2-(2',4'-dihydroxyphenyl)-5,6-methylenedioxybenzofuran (ABF) showing the most potent Results: ABF exhibited stronger anti-proliferative activity against CNE1 and CNE2 cells compared to SDG extract, with a 10-fold lower 48-h IC Conclusion: ABF demonstrates promising anti-NPC potential, providing scientific evidence for the traditional anti-cancer use of SDG. This molecule may serve as a natural lead compound for NPC growth inhibitors.

Indexed as

apoptosisbenzofuran compoundnasopharyngeal carcinomaPI3K/AKT/ mTOR/signaling pathwaySophora tonkinensis Gagnep

Identifiers

PMID42110550
PMCPMC13149249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.